Kyowa Kirin Co., Ltd. (TYO:4151)
Japan
· Delayed Price · Currency is JPY 2,037.00
-20.50 (-1.00%)
Feb 20, 2025, 10:42 AM JST
Kyowa Kirin Revenue
In the year 2024, Kyowa Kirin had annual revenue of 495.56B JPY with 12.06% growth. Kyowa Kirin had revenue of 132.76B in the quarter ending December 31, 2024, a decrease of -2.51%.
Revenue
495.56B
Revenue Growth
+12.06%
P/S Ratio
2.21
Revenue / Employee
87.42M
Employees
5,669
Market Cap
1,080.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | 318.35B | 12.53B | 4.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,170.61B |
| Takeda Pharmaceutical Company | 4,579.02B |
| Daiichi Sankyo Company | 1,795.99B |
| HOYA Corporation | 837.44B |
| Terumo | 1,011.15B |
| Otsuka Holdings | 2,329.86B |
| Astellas Pharma | 1,867.63B |
| Olympus | 993.33B |
Kyowa Kirin News
- 15 days ago - Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies - Benzinga
- 23 days ago - Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe - Business Wire
- 25 days ago - AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform - GlobeNewsWire
- 2 months ago - Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies - Business Wire
- 3 months ago - Kura stock slides 17% on Kyowa Kirin deal for ziftomenib - Seeking Alpha
- 3 months ago - Kura Oncology to partner with Kyowa Kirin for blood cancer therapy - Reuters
- 4 months ago - Kyowa Kirin 9M GAAP EPS of Yen 105.19, revenue of Yen 362.8B - Seeking Alpha
- 4 months ago - Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company - Business Wire